Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 15, 2023, reports on the vesting of Deferred Annual Bonus Plan (DABP) awards granted in 2020 to Persons Discharging Managerial Responsibilities (PDMRs). The three-year restricted period for these nil-cost options concluded on February 14, 2023. The filing details the subsequent exercise of these options and the sale of Ordinary Shares to cover associated tax liabilities.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on executive compensation transactions. Key transaction metrics include:
- Share Price: The closing price of GSK Ordinary Shares on February 14, 2023, was £14.70.
- Transaction Volume: A total of 174,004 Ordinary Shares vested across nine executives at a nil cost (£0.00).
- Tax Sales: A total of 66,073 Ordinary Shares were sold on the London Stock Exchange to meet tax liabilities, with transaction prices ranging between £14.86 and £14.89.
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It documents a scheduled, recurring event under the 2017 Remuneration Policy where deferred bonus awards matured after a three-year restriction period.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, or discussion of corporate risks and contingencies. The transactions were executed in accordance with the shareholder-approved 2017 Remuneration Policy and DABP rules, involving mandatory bonus deferrals.
Investor Verification Checklist
- Verify the total number of shares vested and sold against the company's annual proxy statement or remuneration report.
- Confirm the closing share price of £14.70 on February 14, 2023, against market data.
- Review the 2017 Remuneration Policy to understand the vesting conditions for the 2020 DABP awards.
- Check subsequent filings for any additional insider trading activity by the named executives (e.g., Ms E Walmsley, Mr I Mackay).